These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3197751)

  • 41. Assessment of platelet function in patients with Raynaud's syndrome.
    Hutton RA; Mikhailidis DP; Bernstein RM; Jeremy JY; Hughes GR; Dandona P
    J Clin Pathol; 1984 Feb; 37(2):182-7. PubMed ID: 6229551
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.
    Kunnen JJ; Dahler HP; Doorenspleet JG; van Oene JC
    Eur J Clin Pharmacol; 1988; 34(3):267-71. PubMed ID: 2840293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypertensive patients with Raynaud's phenomenon or intermittent claudication and their treatment with ketanserin.
    van Oene JC
    Drugs; 1988; 36 Suppl 1():148-51. PubMed ID: 3240729
    [No Abstract]   [Full Text] [Related]  

  • 44. Raynaud's disease: a new therapeutic approach with a 5-HT2 receptors blocker.
    Allegra C; Tonelli V; Bonifacio M; Mari A; Assogna G
    Boll Chim Farm; 1985 Oct; 124(10):121S-124S. PubMed ID: 2935173
    [No Abstract]   [Full Text] [Related]  

  • 45. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A; McCans J; Willan AR; Ford PM
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon.
    Coffman JD; Cohen RA
    Clin Sci (Lond); 1994 Mar; 86(3):269-73. PubMed ID: 8156737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of ketanserin in the therapy of Raynaud's phenomenon: thermometric data.
    Arosio E; Montesi G; Zannoni M; Perbellini L; Paluani F; Lechi A
    Angiology; 1991 May; 42(5):408-13. PubMed ID: 2035893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon.
    Wollersheim H; Thien T; Fennis J; van Elteren P; van 't Laar A
    Clin Pharmacol Ther; 1986 Aug; 40(2):219-25. PubMed ID: 3731684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nisoldipine in primary Raynaud's phenomenon.
    Challenor VF; Waller DG; Francis DA; Francis JL; Mani R; Roath S
    Eur J Clin Pharmacol; 1987; 33(1):27-30. PubMed ID: 3691593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.
    Teh LS; Manning J; Moore T; Tully MP; O'Reilly D; Jayson MI
    Br J Rheumatol; 1995 Jul; 34(7):636-41. PubMed ID: 7670782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon.
    Destors JM; Gauthier E; Lelong S; Boissel JP
    Angiology; 1986 Aug; 37(8):565-9. PubMed ID: 2943195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.
    Borawski J; Rydzewski A; Pawlak K; Azzadin A; Buczko W; Mysliwiec M
    Thromb Res; 1998 May; 90(4):171-80. PubMed ID: 9692616
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of Raynaud's syndrome with ketanserin. Clinical, biological and hemodynamic aspects].
    Bellucci S; Kedra AW; Naccache-Herman V; Cambau E; Tobelem G; Caen JP
    Presse Med; 1987 Jul 11-18; 16(27):1335. PubMed ID: 2956601
    [No Abstract]   [Full Text] [Related]  

  • 57. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of Raynaud's phenomenon].
    Lazareth I
    Ann Dermatol Venereol; 1987; 114(8):1035-8. PubMed ID: 2892456
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.